Overview Financials News + Filings Key Docs Charts Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Intellipharmaceutics International Inc. (IPCI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
6-K
| Quarterly results |
| 09/26/2023 |
6-K
| Quarterly results |
| 10/14/2022 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three and nine Months Ended August 31, 2022",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three and nine Months Ended August 31, 2022",
"Intellipharmaceutics Announces Third Quarter 2022 Results Toronto, Ontario October 14, 2022 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted. · In August 2022 the Company announced that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc. , by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 07/21/2022 |
6-K
| Quarterly results |
| 04/14/2022 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three Months Ended February 28, 2022",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three Months Ended February 28, 2022",
"Intellipharmaceutics Announces First Quarter 2022 Results Toronto, Ontario April 14, 2022 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted. · In February 2022 the Company received marketing approval for the Canadian market from Health Canada for generic Pristiq in the 50 and 100 mg strengths. · In November 2021 the Company received final FDA approval for its Dexmethylphenidate Extended-release Capsules in the 5 mg, 10 mg, 30 mg and 40 mg strengths. The 15 ...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 10/15/2021 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three and Nine Months Ended August 31, 2021",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three and Nine Months Ended August 31, 2021",
"Intellipharmaceutics Announces Third Quarter 2021 Results Toronto, Ontario July 15, 2021 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted. ● Effective May 5, 2021 our exclusive license agreements with Tris Pharma, Inc. for generic Seroquel XR®, generic Pristiq® and generic Effexor XR® were mutually terminated. Products were never supplied nor distributed under the licenses. Termination of the exclusive agreements may provide op...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 10/15/2020 |
6-K
| Quarterly results |
| 07/15/2020 |
6-K
| Quarterly results |
| 05/29/2020 |
6-K
| Quarterly results|
Docs:
|
"PRIMARY DOCUMENT",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three Months Ended February 29, 2020",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three Months Ended February 29, 2020",
"Intellipharmaceutics Announces First Quarter 2020 Results Toronto, Ontario May 29, 2020 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 29, 2020. All dollar amounts referenced herein are in United States dollars unless otherwise noted. ● On April 9, 2020, we announced an update on timing of the release of our first quarter financial results for the three months ended February 29, 2020. The Canadian Securities Administrators had announced temporary relief from certain regulatory filings required to be made on or before June 1, 2020 by reporting i...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 10/11/2019 |
6-K
| Quarterly results|
Docs:
|
"PRIMARY DOCUMENT",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three and Nine Months Ended August 31, 2019",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three and Nine Months Ended August 31, 2019",
"Intellipharmaceutics Announces Third Quarter 2019 Results Toronto, Ontario October 11, 2019 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2019. All dollar amounts referenced herein are in United States dollars unless otherwise noted. ● On October 4, 2019, we announced that following the filing of a bankruptcy stay by Purdue Pharma L.P., the Company’s ongoing litigation cases, number 1:17-cv-00392-RGA and 1:18-cv-00404-RGA-SRF between Purdue Pharma L.P. et al and Intellipharmaceutics, have been stayed and the existing trial dates in ...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 07/10/2019 |
6-K
| Quarterly results|
Docs:
|
"PRIMARY DOCUMENT",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three and Six Months Ended May 31, 2019",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three and Six Months Ended May 31, 2019",
"Intellipharmaceutics Announces Second Quarter 2019 Results Toronto, Ontario July 10, 2019 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2019. All dollar amounts referenced herein are in United States dollars unless otherwise noted. Corporate Developments ● On July 8, 2019, we announced that the Company has obtained an equity financing commitment of up to $10,000,000 from Silverback Capital Corporation, a private investment firm . During the 36-month term of the equity financing commitment, we may sell shares of our common stock to Silve...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 10/15/2018 |
6-K
| Quarterly results |
| 07/16/2018 |
6-K
| Quarterly results|
Docs:
|
"PRIMARY DOCUMENT",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three and Six Months Ended May 31, 2018",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three and Six Months Ended May 31, 2018",
"Intellipharmaceutics Announces Second Quarter 2018 Results Toronto, Ontario July 16, 2018 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2018. All dollar amounts referenced herein are in United States dollars unless otherwise noted. Second Quarter 2018 Highlights ● Second quarter 2018 revenues $0.6 million versus $2.0 million in second quarter 2017 ● Commenced Category 2 and 3 human abuse liability studies for our Oxycodone ER product candidate ● Completed two financings for total of $5.3 million “While we are disapp...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 04/16/2018 |
6-K
| Quarterly results |
| 10/10/2017 |
6-K
| Quarterly results |
| 07/11/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 04/11/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
|
|